SIMBRINZA® Suspension reduced IOP when added to a PGA1

SIMBRINZA® Suspension should be taken at least five (5) minutes apart from other topical ophthalmic drugs.2

Delivered up to 7.1 mm Hg additional IOP reduction from baseline when added to a PGA1


IOP Control Throughout the Day chart
Primary End Point1
  • Mean diurnal IOP (IOP averaged over all daily time points) at week 6 between treatment groups
Key Secondary End Points1
  • Mean IOP for each daily time point at week 6
  • Mean diurnal change from baseline to week 6

*Differences (mm Hg) at week 6 time points between treatment groups were -2.1 (P=0.0002), -4.6 (P<0.0001), -2.8 (P<0.0001), and -4.4 (P<0.0001)1

5.7 mm Hg additional mean diurnal IOP reduction from baseline at week 6 when added to a PGA1


STUDY DESIGN1

A prospective, randomized, multicenter, double-blind, parallel-group study of 182 patients with open-angle glaucoma and/or ocular hypertension receiving treatment with a PGA. PGA treatment consisted of travoprost, latanoprost, or bimatoprost. Patients in the study were randomized to adjunctive treatment with SIMBRINZA® Suspension (n=88) or vehicle (n=94). The primary efficacy end point was mean diurnal IOP (IOP averaged over all daily time points) at week 6 between treatment groups. Key secondary end points included mean IOP at week 6 for each daily time point (8 AM, 10 AM, 3 PM, and 5 PM) and mean diurnal IOP change from baseline to week 6.

References: 1. Fechtner RD, Myers JS, Hubatsch DA, Budenz DL, DuBiner HB. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial [published online July 1, 2016]. Eye (Lond). 2016;30(10):1343-1350. doi:10.1038/eye.2016.126. 2. SIMBRINZA® Suspension [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; 2015.